P-631. A Practice-Based and Expert-Driven Consensus on the Management of Respiratory and Non-Respiratory Adverse Events Associated with Amikacin Liposome Inhalation Suspension (ALIS)
Colin Swenson, Charles L Daley, Jennifer Faber-Gerling, Patrick A Flume, Shannon H Kasperbauer, H Jeffrey Kim, Amy Leitman, Theodore K Marras, Kozo Morimoto, Kenneth N Olivier, Kevin L Winthrop, Juzar Ali
TL;DR
Experts developed guidelines to manage side effects of a new treatment for a lung disease caused by Mycobacterium avium complex.
Contribution
A multidisciplinary expert consensus provides practical recommendations for managing adverse events of ALIS in MAC-LD patients.
Findings
A multidisciplinary team approach is recommended to improve treatment adherence.
Expert opinion-based strategies are proposed due to limited published data.
Patient education and clinical team involvement are emphasized for successful AE management.
Abstract
Amikacin liposome inhalation suspension (ALIS), a nebulized formulation of amikacin, is the first treatment approved in the United States, as part of a combination therapy, for adults with refractory Mycobacterium avium complex lung disease (MAC-LD) who have limited or no alternative treatment options. In clinical studies, ALIS treatment was associated with adverse events (AEs) of mild or moderate severity which led to treatment discontinuation in up to 24.4% of patients. In clinical practice, inadequate management of AEs may lead to decreased treatment adherence and early discontinuation. An expert steering committee (SC) convened to establish practice-based, and expert-agreed recommendations for the mitigation strategies of ALIS-related AEs for patients with MAC-LD, with the aim of providing up-to-date practical recommendations for healthcare professionals. The SC included: 7…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMycobacterium research and diagnosis · Cystic Fibrosis Research Advances · Respiratory and Cough-Related Research